Muscular Dystrophy. Biol 405 Molecular Medicine
|
|
- Posy Richard
- 5 years ago
- Views:
Transcription
1 Muscular Dystrophy Biol 405 Molecular Medicine
2 Duchenne muscular dystrophy Duchenne muscular dystrophy is a neuromuscular disease that occurs in ~ 1/3,500 male births. The disease causes developmental delays e.g. late onset of walking. By the age of 3-5 years complaints include leg weakness i.e. running and climbing difficulties. Subsequently, gradual muscle wasting occurs leading to loss of ambulation by age 12. Death frequently occurs in the late teens or early twenties as a consequence of respiratory failure (through weakening of the diaphragm).
3 Becker muscular dystrophy The usual arrangement of fibres is disrupted and there is marked degeneration, regeneration and fibrosis in the muscles. Becker muscular dystrophy affects ~ 1/30,000 male births. Course is much more variable and less severe than Duchenne muscular dystrophy. Consequently, many Becker patients remain ambulatory into adulthood and live full and minimally restricted lives. Both dystrophies involve loss of individual muscle fibres and represent different degrees of severity of essentially the same disease.
4 The dystrophin gene Unequal gender distribution indicates that the gene is on the X chromosome. Analysis of the gene proved to be difficult because there was no prior knowledge of the nature of the gene product. Initial strategies depended upon mapping the large numbers of mutations causing the disease. The gene spans ~ 2.5 million base pairs of genomic DNA. It consists of at least 70 exons and gives rise to a 14kb transcript that encodes dystrophin (Mr ~ 427,000). The large size of the gene probably accounts for its high mutation rate.
5 The dystrophin protein The dystrophin gene codes for several protein products. Three different promoters control the expression of different products in muscle, brain and other non-muscle tissues respectively. Alternative splicing also occurs. The dystrophin protein found in muscle is composed of four structural domains. Dystrophin is stained brown in normal muscle (left), but is absent in muscle from a boy with DMD (right).
6 Severe BMD Cramps and/or weakness BMD DMD BMD Hinge region 1 - actin binding N-terminus 2 - triple helical domain 3 - calcium binding region? 4 - carboxyl terminus - interaction with glycoprotein? The Dystrophin Protein 1 shows homology to the actin-binding regions of -actinin and -spectrin. 2 consists of a series of amino acid repeats, which form a triple helical structure. The repeats are interrupted by proline-rich hinge regions that add flexibility to the molecule. 3 is similar to the Ca 2+ binding region of -actinin. 4 is similar to the carboxyl terminus of the chromosome 6- encoded dystrophin-related protein (utropin).
7 Dystropin-like proteins A 71 kda protein - expressed by internal promoter between exons 62 and 63 of the dystrophin gene. Contains 583 out of the 610 amino acids of the cys-rich and carboxyl terminus domains of the dystrophin protein, this core is flanked by unique amino- and carboxyl terminus sequences. An 87 kda protein encoded by a separate gene. This is a component of the acetylcholine receptor-rich postsynaptic membranes from electric tissues. Its core is modestly homologous to the dystrophin cys-rich and carboxyl terminus domains.
8 Immunocytochemical mapping has shown that dystrophin is expressed on the inner face of plasma membranes of smooth, cardiac, and striated muscle as part of a glycoprotein complex (it is also expressed in specifc neurones). The protein appears to be part of the cytoskeleton and, as such, interacts with a variety membrane proteins. Overall the function, of dystrophin is to act as a molecular 'shock absorber' protecting the plasma membrane from the stresses developed during muscle contraction.
9
10 Diagnosis Southern blotting can be used to test for deletions in the coding sequence of the dystrophin gene. With the aid of PCR technology, deletions, or duplications, of one or more exons can be detected in approximately 65% of dystrophic patients. The remaining 35% of patients have more subtle alterations such as splicing mutations or point mutations in the coding sequence. Some of these mutations are detectable by mrna RT-PCR.
11 Immunoblotting of muscle proteins from tissue biopsies allows the identification of altered size dystrophin mutants. The total absence of dystrophin predicts Duchenne muscular dystrophy with 99% accuracy. The presence of larger or smaller sized dystrophins and/or reduced abundance of dystrophin predicts Becker muscular dystrophy with 95% accuracy.
12 Severe BMD Cramps and/or weakness BMD DMD BMD Hinge region 1 - actin binding N-terminus 2 - triple helical domain 3 - calcium binding region? 4 - carboxyl terminus - interaction with glycoprotein? The Dystrophin Protein Deletions within domain 1 result in low levels of dystrophin and the more severe phenotypes. This domain binds actin and deletions might be expected to reduce protein stability by disrupting interactions with other components of the cytoskeleton. The phenotypes of patients with deletions or duplications within domain 2 are more variable.
13 Severe BMD Cramps and/or weakness BMD DMD BMD Hinge region 1 - actin binding N-terminus 2 - triple helical domain 3 - calcium binding region? 4 - carboxyl terminus - interaction with glycoprotein? The Dystrophin Protein Loss of the middle section of domain 2 causes a very mild phenotype. If domain 2 only provides size then deletions may be predicted to have minimal impact. Deletions around exons cause Becker muscular dystrophy. Phenotypic variability suggests that environmental factors may play important roles in clinical progression. Domain 3 and the proximal region of domain 4 are apparently essential - loss leads to Duchenne muscular dystrophy. Loss of the terminal portion of domain 4 is associated with mild Becker muscular dystrophy.
14 Prevention and possible treatment Prevention relies on the identification of (female) carriers with demonstrable mutations and on prenatal diagnosis from foetal cells. Unfortunately the high spontaneous mutation rate of the dystrophin gene limits the effectiveness of these techniques. Infant screening for serum creatine kinase may allow identification of affected children.
15 Subcellular structures and pathways of a skeletal muscle fibre targeted in treatment strategies.
16 Gene Therapy There are a number of obstacles to successful gene therapy: Large size of the human skeletal muscle volume. Vectors needed that can deliver and appropriately express dystrophin only in skeletal muscle. Immunological problems - if the immune system has never seen a protein (dystrophin) it may mount an autoimmune response to it. Adenoviral vectors, gutted of almost the entire viral genome, are potentially useful as there should be few immunological problems with viral proteins. Use of antisense oligonucleotides to force alternative splicing around mutations - thus restoring reading frame and converting a Duchene phenotype to the milder Becker phenotype may be a useful approach.
17
18 Gene therapy and cell (myoblast) transplantation may be combined i.e. transplantation of genetically modified myoblasts. e.g. derive a primary culture from a patient s muscle biopsy, then carry out adenovirus-mediated dystrophin gene transfer into these cultures with subsequent expression of the dystrophin transgene. The transduced cultures can then, hopefully, be transplanted back into the patient. An alternative approach may lie in the identification of proteins similar to dystrophin. The expression of such proteins (e.g. the chromosome 6 encoded dystrophinrelated protein) may be up-regulated, by appropriate pharmacological agents, to compensate for the absence of dystrophin. Adult stem cells producing dystrophin in dystrophin-deficient mice.
19 Summary Duchenne muscular dystrophy is a neuromuscular disease that occurs in ~ 1/3,500 male births. The milder Becker muscular dystrophy affects ~ 1/30,000 male births. The dystrophin gene consists of at least 70 exons and encodes the dystrophin protein (Mr ~ 427,000). Dystrophin acts as a molecular 'shock absorber' protecting the plasma membrane from the stresses developed during muscle contraction. The absence of dystrophin predicts Duchenne muscular dystrophy with 99% accuracy. Larger or smaller sized dystrophins and/or reduced abundance predicts Becker muscular dystrophy with 95% accuracy. The high spontaneous mutation rate of the dystrophin gene prevents reliable identification of carriers or prenatal diagnosis. There are considerable obstacles to successful gene therapy.
20 References Le Rumeur, E. et al., (2010) Biochim. Biophys. Acta 1804, dystrophin structure. Vilquin, J.-T. et al., (2011) Curr. Opin. Organ Transplant. 16, Cell therapy for muscular dystrophies. Hoffman, E. P. et al., (2011) Am. J. Pathol. 179, Exon skipping and stop codon read through. Goyenvalle, A. et al., (2011) Hum. Molec. Gen. 20, R69-R78. Therapeutic approaches to muscular dystrophy. Sahenk, Z. & Mendell, J. R. (2011) Curr. Rheumatol. Rep. 13, Distinct pathogenic mechanisms and novel therapeutic strategies.
Corporate Medical Policy
Corporate Medical Policy Genetic Testing for Duchenne and Becker Muscular Dystrophy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_duchenne_and_becker_muscular_dystrophy
More informationDMD Genetics: complicated, complex and critical to understand
DMD Genetics: complicated, complex and critical to understand Stanley Nelson, MD Professor of Human Genetics, Pathology and Laboratory Medicine, and Psychiatry Co Director, Center for Duchenne Muscular
More informationMutations. A2 Biology For WJEC
12. Mutation is a change in the amount, arrangement or structure in the DNA of an organism. 13. There are two types of mutations, chromosome mutations and gene mutations. Mutations A2 Biology For WJEC
More informationUnderstanding genetics, mutation and other details. Stanley F. Nelson, MD 6/29/18
Understanding genetics, mutation and other details Stanley F. Nelson, MD 6/29/18 1 6 11 16 21 Duchenne muscular dystrophy 26 31 36 41 46 51 56 61 66 71 76 81 86 91 96 600 500 400 300 200 100 0 Duchenne/Becker
More informationGene therapy and genome editing technologies for the study and potential treatment of :
WORKSHOP ON GENOME EDITING Gene therapy and genome editing technologies for the study and potential treatment of : Duchenne Muscular Dystrophy by Dr France Piétri-Rouxel, Institut de Myologie Centre de
More informationSMA IS A SEVERE NEUROLOGICAL DISORDER [1]
SMA OVERVIEW SMA IS A SEVERE NEUROLOGICAL DISORDER [1] Autosomal recessive genetic inheritance 1 in 50 people (approximately 6 million Americans) are carriers [2] 1 in 6,000 to 1 in 10,000 children born
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Highly Specialised Technology Evaluation
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Highly Specialised Technology Evaluation Drisapersen for treating Duchenne muscular Draft scope (pre-referral) Draft remit/evaluation objective
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29354 holds various files of this Leiden University dissertation. Author: Straathof, Chiara Title: dystrophinopathies : heterogeneous clinical aspects of
More informationPaula Clemens NS-065/NCNP-01 Study Chair
A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD) Paula Clemens NS-065/NCNP-01 Study
More informationSubject: Eteplirsen (Exondys 51)
09-J2000-69 Original Effective Date: 10/15/16 Reviewed: 12/12/18 Revised: 01/01/19 Next Review: 12/11/18 Subject: Eteplirsen (Exondys 51) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationSALSA MLPA KIT P060-B2 SMA
SALSA MLPA KIT P6-B2 SMA Lot 111, 511: As compared to the previous version B1 (lot 11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). Please note that, in contrast to the
More informationGenetic diagnosis of limb girdle muscular dystrophy type 2A, A Case Report
Genetic diagnosis of limb girdle muscular dystrophy type 2A, A Case Report Roshanak Jazayeri, MD, PhD Assistant Professor of Medical Genetics Faculty of Medicine, Alborz University of Medical Sciences
More informationMuscular Dystrophies. Pinki Munot Consultant Paediatric Neurologist Great Ormond Street Hospital Practical Neurology Study days April 2018
Muscular Dystrophies Pinki Munot Consultant Paediatric Neurologist Great Ormond Street Hospital Practical Neurology Study days April 2018 Definition and classification Clinical guide to recognize muscular
More informationCurrent Research Strategies and Therapeutic Approaches in Duchenne Muscular Dystrophy
Current Research Strategies and Therapeutic Approaches in Duchenne Muscular Dystrophy H. Lee Sweeney, Ph.D. Department of Physiology University of Pennsylvania Perelman School of Medicine Current Research
More informationMRC-Holland MLPA. Description version 19;
SALSA MLPA probemix P6-B2 SMA Lot B2-712, B2-312, B2-111, B2-511: As compared to the previous version B1 (lot B1-11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). SPINAL
More informationTreatment of Duchenne Muscular Dystrophy with Oligonucleotides
Treatment of Duchenne Muscular Dystrophy with Oligonucleotides against an Exonic Splicing Enhancer Sequence Masafumi Matsuo, Mariko Yagi and Yasuhiro Takeshima Department of Pediatrics, Kobe University
More informationEdasalonexent (CAT-1004) Program
Edasalonexent (CAT-1004) Program Oral small molecule designed to inhibit NF-κB for the treatment of Duchenne muscular dystrophy Joanne M. Donovan, MD, PhD Chief Medical Officer, Catabasis Pharmaceuticals
More informationREAD ORPHA.NET WEBSITE ABOUT BETA-SARCOGLYOCANOPATHY LIMB-GIRDLE MUSCULAR DYSTROPHIES
READ ORPHA.NET WEBSITE ABOUT BETA-SARCOGLYOCANOPATHY LIMB-GIRDLE MUSCULAR DYSTROPHIES (LGMD) Limb-girdle muscular dystrophies (LGMD) are a heterogeneous group of genetically determined disorders with a
More informationBiochemistry #02. The biochemical basis of skeletal muscle and bone disorders Dr. Nabil Bashir Bara Sami. 0 P a g e
]Type text[ ]Type text[ ]Type text[ Biochemistry #02 The biochemical basis of skeletal muscle and bone disorders Dr. Nabil Bashir Bara Sami 0 P a g e Greetings everyone, ladies and gentlemen The biochemical
More informationMuscle Metabolism. Dr. Nabil Bashir
Muscle Metabolism Dr. Nabil Bashir Learning objectives Understand how skeletal muscles derive energy at rest, moderate exercise, and strong exercise. Recognize the difference between aerobic and anaerobic
More informationCHAPTER 6 2/9/2016. Learning Objectives List the four traits that all muscle types have in common.
Learning Objectives List the four traits that all muscle types have in common. CHAPTER 6 The Muscular System Demonstrate and explain the use of antagonistic muscle pairs. Describe the attachment of muscle
More informationThe functional role of dystrophin in the heart: implications for inherited and non-inherited heart disease. Matthew Scott Barnabei
The functional role of dystrophin in the heart: implications for inherited and non-inherited heart disease by Matthew Scott Barnabei A dissertation submitted in partial fulfillment of the requirements
More informationDSS-1. No financial disclosures
DSS-1 No financial disclosures Clinical History 9 year old boy with past medical history significant for cerebral palsy, in-turning right foot, left clubfoot that was surgically corrected at 3 years of
More informationDuchenne muscular dystrophy quantification of muscular parameters and prednisone therapy Beenakker, Ernesto Alexander Christiaan
University of Groningen Duchenne muscular dystrophy quantification of muscular parameters and prednisone therapy Beenakker, Ernesto Alexander Christiaan IMPORTANT NOTE: You are advised to consult the publisher's
More informationProteins. Length of protein varies from thousands of amino acids to only a few insulin only 51 amino acids
Proteins Protein carbon, hydrogen, oxygen, nitrogen and often sulphur Length of protein varies from thousands of amino acids to only a few insulin only 51 amino acids During protein synthesis, amino acids
More informationMuscular System. Disorders & Conditions
Muscular System Disorders & Conditions Fibromyalgia Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Often is described
More informationHow to go around conducting a clinical trial in small populations: Duchenne muscular dystrophy
How to go around conducting a clinical trial in small populations: Duchenne muscular dystrophy CTs in rare diseases London 30 th November 2015 Michela Guglieri JWMDRC Newcastle upon Tyne Michela.guglieri@Newcastle.ac.uk
More informationBIOL212 Biochemistry of Disease. Metabolic Disorders - Obesity
BIOL212 Biochemistry of Disease Metabolic Disorders - Obesity Obesity Approx. 23% of adults are obese in the U.K. The number of obese children has tripled in 20 years. 10% of six year olds are obese, rising
More informationProtocol. Genetic Testing for Duchenne and Becker Muscular Dystrophy
Protocol Genetic Testing for Duchenne and Becker Muscular Dystrophy (20486) Medical Benefit Effective Date: 10/01/17 Next Review Date: 05/18 Preauthorization Yes Review Dates: 05/13, 05/14, 05/15, 05/16,
More informationExercise induced cramps and myoglobinuria in dystrophinopathy a report of three Malaysian patients
Neurology Asia 2010; 15(2) : 125 131 Exercise induced cramps and myoglobinuria in dystrophinopathy a report of three Malaysian patients 1 Azlina Ahmad Annuar, 2 Kum Thong Wong, 1 Ai Sze Ching, 3 Meow Keong
More informationClinical Policy: Eteplirsen Reference Number: NH.PHAR.288 Effective Date: 12/16
Clinical Policy: Reference Number: NH.PHAR.288 Effective Date: 12/16 Last Review Date: 12/17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationImplementation of Newborn Screening for Duchenne Muscular Dystrophy.
Implementation of Newborn Screening for Duchenne Muscular Dystrophy. Michele A. Lloyd-Puryear, MD, PhD 1, Stuart J Moat, PhD 2, Amy Brower 3, PhD, Annie Kennedy 1, Petra Furu 4, Michael Watson, PhD 3,
More informationClinical Policy Title: Genetic tests for Duchenne muscular dystrophy
Clinical Policy Title: Genetic tests for Duchenne muscular dystrophy Clinical Policy Number: 02.01.23 Effective Date: February 1, 2017 Initial Review Date: January 18, 2017 Most Recent Review Date: January
More informationDifferences in carrier frequency between mothers of Duchenne and Becker muscular dystrophy patients
(2014) 59, 46 50 & 2014 The Japan Society of Human Genetics All rights reserved 1434-5161/14 www.nature.com/jhg OPEN ORIGINAL ARTICLE Differences in carrier frequency between mothers of Duchenne and Becker
More informationProfile, types, duration and severity of muscular dystrophy: a clinical study at a tertiary care hospital
International Journal of Advances in Medicine Viswajyothi P et al. Int J Adv Med. 2018 Jun;5(3):700-704 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20182126
More informationGene therapy of monogenic diseases
Gene therapy of monogenic diseases Hemophilia Cystic fibrosis Duchenne muscular dystrophy Lecture 12 7th January 2013 1 Disease targets for gene therapy Disease Cystic fibrosis Gaucher disease Hemophilia
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Exondys 51) Reference Number: CP.PHAR.288 Effective Date: 12.01.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Exondys 51) Reference Number: CP.CPA.188 Effective Date: 02.15.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More information-- Single Global Phase 3 Trial Expected to Begin in First Half of
Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment -- Consistent
More information-19. -Mousa Salah. -Shahd Alqudah. -Dr Belal
التزام -19 -Mousa Salah -Shahd Alqudah -Dr Belal 1 P a g e In the previous lecture we talked about the numerical chromosomal abnormalities, they are either autosomal or sex, and we said that the chromosomal
More informationIdentification and characterization of multiple splice variants of Cdc2-like kinase 4 (Clk4)
Identification and characterization of multiple splice variants of Cdc2-like kinase 4 (Clk4) Vahagn Stepanyan Department of Biological Sciences, Fordham University Abstract: Alternative splicing is an
More informationSupplementary Figure 1. AdipoR1 silencing and overexpression controls. (a) Representative blots (upper and lower panels) showing the AdipoR1 protein
Supplementary Figure 1. AdipoR1 silencing and overexpression controls. (a) Representative blots (upper and lower panels) showing the AdipoR1 protein content relative to GAPDH in two independent experiments.
More informationTypes of Muscle. Skeletal striated & voluntary Smooth involuntary Cardiac - heart
Muscular System Types of Muscle Skeletal striated & voluntary Smooth involuntary Cardiac - heart The word striated means striped. Skeletal muscle appears striped under a microscope. Muscles and Muscle
More informationMutation specific therapies
Taken from www.dmd.nl/gt. Used with permission Mutation specific therapies Introduction Two therapies for Duchenne patients are currently being tested in clinical trials, which are applicable only to patients
More informationMRC-Holland MLPA. Description version 07; 26 November 2015
SALSA MLPA probemix P266-B1 CLCNKB Lot B1-0415, B1-0911. As compared to version A1 (lot A1-0908), one target probe for CLCNKB (exon 11) has been replaced. In addition, one reference probe has been replaced
More informationExondys 51 (eteplirsen) injection Policy Number: Last Review: 10/2018 Origination: 10/2016 Next Review: 10/2019
Exondys 51 (eteplirsen) injection Policy Number: 5.01.618 Last Review: 10/2018 Origination: 10/2016 Next Review: 10/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage
More informationMuscular System Module 3: Contraction and Relaxation *
OpenStax-CNX module: m48498 1 Muscular System Module 3: Contraction and Relaxation * Donna Browne Based on Muscle Fiber Contraction and Relaxation by OpenStax This work is produced by OpenStax-CNX and
More informationThe Pathogenesis and Therapy of Muscular Dystrophies
I GG16CH13-Davies ARI 11 May 2015 13:45 R E V I E W S Review in Advance first posted online on June 4, 2015. (Changes may still occur before final publication online and in print.) E N C A D V A N The
More informationBio 111 Study Guide Chapter 17 From Gene to Protein
Bio 111 Study Guide Chapter 17 From Gene to Protein BEFORE CLASS: Reading: Read the introduction on p. 333, skip the beginning of Concept 17.1 from p. 334 to the bottom of the first column on p. 336, and
More informationCARE CONSIDERATIONS FOR DUCHENNE MUSCULAR DYSTROPHY
IMPORTANT NEW UPDATE A Summary of the Report of the DMD Care Considerations Working Group Intended for US healthcare professionals only. CARE CONSIDERATIONS FOR DUCHENNE MUSCULAR DYSTROPHY Full article
More informationEdasalonexent (CAT-1004)
Edasalonexent (CAT-1004) An NF-κB Inhibitor in Development for Patients with Duchenne Muscular Dystrophy Joanne M. Donovan, MD PhD Chief Medical Officer 17 February 2018 1 Forward Looking Statements This
More informationCatabasis Pharmaceuticals Q May 2018
Catabasis Pharmaceuticals Q1 2018 May 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including
More informationChapter 11. Chromosomes and Human Inheritance
Chapter 11 Chromosomes and Human Inheritance Human Chromosomes Human body cells have 23 pairs of homologous chromosomes 22 pairs of autosomes 1 pair of sex chromosomes Autosomesand Sex Chromosomes Paired
More informationChapter 12-4 DNA Mutations Notes
Chapter 12-4 DNA Mutations Notes I. Mutations Introduction A. Definition: Changes in the DNA sequence that affect genetic information B. Mutagen= physical or chemical agent that interacts with DNA to cause
More informationChapter Skeletal Muscle Structure and Function
Chapter 10.2 Skeletal Muscle Structure and Function Introduction to Muscle Physiology Movement is a fundamental characteristic of all living things All muscle cells (skeletal, cardiac, and smooth) are
More informationScreening of dystrophin gene deletions in Egyptian patients with DMD/BMD muscular dystrophies
125 Screening of dystrophin gene deletions in Egyptian patients with DMD/BMD muscular dystrophies Laila K. Effat a, Ashraf A. El-Harouni a, Khalda S. Amr a, Tarik I. El-Minisi b, Nagwa Abdel Meguid a and
More informationInsulin Resistance. Biol 405 Molecular Medicine
Insulin Resistance Biol 405 Molecular Medicine Insulin resistance: a subnormal biological response to insulin. Defects of either insulin secretion or insulin action can cause diabetes mellitus. Insulin-dependent
More informationRAS Genes. The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes.
۱ RAS Genes The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes. Oncogenic ras genes in human cells include H ras, N ras,
More informationGenetics, The Duchenne Registry and Your Family! Jen Ely, MS, CGC June 2, 2018
Genetics, The Duchenne Registry and Your Family! Jen Ely, MS, CGC June 2, 2018 The Duchenne Registry Team Two Genetic Counselors to help you: Ann Martin, MS, CGC Jen Ely, MS, CGC Registry also supported
More informationExon skipping in a DCM mouse model mimicking a human mutation in titin
Exon skipping in a DCM mouse model mimicking a human mutation in titin Dr. Michael Gramlich Department of Cardiology, University of Tuebingen, Germany I do not have a financial interest/arrangement or
More informationSkeletal Muscle and the Molecular Basis of Contraction. Lanny Shulman, O.D., Ph.D. University of Houston College of Optometry
Skeletal Muscle and the Molecular Basis of Contraction Lanny Shulman, O.D., Ph.D. University of Houston College of Optometry Like neurons, all muscle cells can be excited chemically, electrically, and
More informationCardiac Considerations and Care in Children with Neuromuscular Disorders
Cardiac Considerations and Care in Children with Neuromuscular Disorders - importance of early and ongoing treatment, management and available able medications. Dr Bo Remenyi Department of Cardiology The
More informationاهتحانات الشهادة الثانىية العاهة فرع علىم الحياة هسابقة في هادة علىم الحياة الودة: ثالث ساعات
وزارة التربية والتعلين العالي الوديرية العاهة للتربية دائرة االهتحانات اهتحانات الشهادة الثانىية العاهة فرع علىم الحياة هسابقة في هادة علىم الحياة الودة: ثالث ساعات االسن: الرقن: دورة سنة 2009 العادية
More informationTransgenic Mice and Genetargeting
Transgenic Mice and Genetargeting mice In Biomedical Science Techniques of transgenic and gene-targeting mice are indispensable for analyses of in vivo functions of particular genes and roles of their
More informationMRC-Holland MLPA. Description version 14; 28 September 2016
SALSA MLPA probemix P279-B3 CACNA1A Lot B3-0816. As compared to version B2 (lot B2-1012), one reference probe has been replaced and the length of several probes has been adjusted. Voltage-dependent calcium
More informationSaman Eghtesad. Bachelor of Science with Honors, University of New Mexico, Submitted to the Graduate Faculty of
Effects of manipulating the immune system on dystrophin gene transfer and dystrophic phenotype in striated muscles of Duchenne muscular dystrophy model, mdx mouse by Saman Eghtesad Bachelor of Science
More informationExperience in Developing a Treatment for Duchenne Muscular Dystrophy
Experience in Developing a Treatment for Duchenne Muscular Dystrophy Pleae Edward M. Kaye MD Chief Medical Officer & SVP The Cause of Duchenne Muscular Dystrophy is the Lack of Dystrophin (
More informationGene Medicines for Exon Skipping
Gene Medicines for Exon Skipping Steve Wilton, Penny Harding and Sue Fletcher Experimental Molecular Medicine Group & the NDC Genotyping Facility Centre for Neuromuscular and Neurological Disorders University
More informationProsensa Corporate Overview Jefferies Healthcare Conference London, UK November 19, Hans Schikan, CEO
Prosensa Corporate Overview Jefferies Healthcare Conference London, UK November 19, 2014 Hans Schikan, CEO Forward-Looking Statements This presentation may contain statements that constitute forward-looking
More informationMultiple exon skipping strategies to by-pass dystrophin mutations
Available online at www.sciencedirect.com Neuromuscular Disorders 22 (2012) 297 305 www.elsevier.com/locate/nmd Multiple exon skipping strategies to by-pass dystrophin mutations Carl F. Adkin a, Penelope
More informationGene Therapy With a Difference By ANDREW POLLACK
September 23, 2013 Gene Therapy With a Difference By ANDREW POLLACK Terri Ellsworth is convinced that her 12-year-old son Billy, who has Duchenne muscular dystrophy, is being helped by an experimental
More informationIowa Wellstone Center Muscle Tissue and Cell Culture Repository
Iowa Wellstone Center Muscle Tissue and Cell Culture Repository Steven A. Moore, M.D., Ph.D. The University of Iowa Department of Pathology and Iowa Wellstone Muscular Dystrophy Cooperative Research Center
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Choroideremia OMIM number for disease 303100 Disease alternative names please
More informationHST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007
MIT OpenCourseWare http://ocw.mit.edu HST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms.
More informationAnalysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationBIO360 Fall 2013 Quiz 1
BIO360 Fall 2013 Quiz 1 1. Examine the diagram below. There are two homologous copies of chromosome one and the allele of YFG carried on the light gray chromosome has undergone a loss-of-function mutation.
More informationPredicted and observed sizes of dystrophin in some patients with gene deletions that disrupt the open reading frame
892 8 Med Genet 1992; 29: 892-896 Muscular Dystrophy Group Research Laboratories, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne NE4 6BE. L V B Nicholson K M D Bushby M
More informationBIOL2005 WORKSHEET 2008
BIOL2005 WORKSHEET 2008 Answer all 6 questions in the space provided using additional sheets where necessary. Hand your completed answers in to the Biology office by 3 p.m. Friday 8th February. 1. Your
More informationDisorders of Muscle. Disorders of Muscle. Muscle Groups Involved in Myopathy. Needle Examination of EMG. History. Muscle Biopsy
Disorders of Muscle Disorders of Muscle Zakia Bell, M.D. Associate Professor of Neurology and Physical Medicine & Rehabilitation Virginia Commonwealth University Cardinal symptom of diseases of the muscle
More information-- Edasalonexent Substantially Slowed Duchenne Muscular Dystrophy Disease Progression through 36 Weeks --
Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial
More informationPre-mRNA has introns The splicing complex recognizes semiconserved sequences
Adding a 5 cap Lecture 4 mrna splicing and protein synthesis Another day in the life of a gene. Pre-mRNA has introns The splicing complex recognizes semiconserved sequences Introns are removed by a process
More informationMuscle Physiology. Dr. Ebneshahidi Ebneshahidi
Muscle Physiology Dr. Ebneshahidi Skeletal Muscle Figure 9.2 (a) Functions of the muscular system 1. Locomotion body movements are due to skeletal muscle contraction. 2. Vasoconstriction and vasodilatation
More informationChapter 10 Muscle Tissue and Physiology Chapter Outline
Chapter 10 Muscle Tissue and Physiology Chapter Outline Module 10.1 Overview of muscle tissue (Figures 10.1 10.2) A. Types of Muscle Tissue (Figure 10.1) 1. The three types of cells in muscle tissue are,,
More informationCAREGIVER PERCEPTIONS AND ADOLESCENT QUALITY OF LIFE IN DUCHENNE MUSCULAR DYSTROPHY. Julia Rae Stone. BS, University of California, Davis, CA, 2014
CAREGIVER PERCEPTIONS AND ADOLESCENT QUALITY OF LIFE IN DUCHENNE MUSCULAR DYSTROPHY by Julia Rae Stone BS, University of California, Davis, CA, 2014 Submitted to the Graduate Faculty of the Department
More informationFunctional significance of dystrophin positive fibres
632 Muscular Dystrophy Group Research Laboratories, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne L V B Nicholson M A Johnson K M D Bushby D Gardner-Medwin Correspondence
More informationSmooth Muscle. Spindle shaped 1/10 th Skel. Musc. cell width 1/1000s Skel. Musc. cell length Some endomysium (No Peri- or Epi-) Organized into sheets
Smooth Muscle Spindle shaped 1/10 th Skel. Musc. cell width 1/1000s Skel. Musc. cell length Some endomysium (No Peri- or Epi-) Organized into sheets Typically two outside [longi] inside [circ] Innervation
More information22q11.2 DELETION SYNDROME. Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona)
22q11.2 DELETION SYNDROME Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona) Genomic disorders GENOMICS DISORDERS refers to those diseases
More informationNew Drug Evaluation: Eteplirsen injection, intravenous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPhenylketonuria (PKU) the Biochemical Basis. Biol 405 Molecular Medicine
Phenylketonuria (PKU) the Biochemical Basis Biol 405 Molecular Medicine PKU a history In 1934 Følling identified a clinical condition - imbecillitas phenylpyruvica. Mental retardation associated with this
More informationChapter 9 Muscle. Types of muscle Skeletal muscle Cardiac muscle Smooth muscle. Striated muscle
Chapter 9 Muscle Types of muscle Skeletal muscle Cardiac muscle Smooth muscle Striated muscle Chapter 9 Muscle (cont.) The sliding filament mechanism, in which myosin filaments bind to and move actin
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Amyotrophic Lateral Sclerosis 10 (ALS10) and Amyotrophic Lateral Sclerosis 6 (ALS6)
More informationMRC-Holland MLPA. Description version 30; 06 June 2017
SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0517, C1-0114. As compared to the previous B2 version (lot B2-0813, B2-0912), 11 target probes are replaced or added, and 10 new reference probes are
More informationLeucine and exercise improve skeletal muscle function in the mdx mouse. Kevin Andrew Voelker
Leucine and exercise improve skeletal muscle function in the mdx mouse Kevin Andrew Voelker Dissertation submitted to the faculty of the Virginia Polytechnic Institute and State University in partial fulfillment
More informationSEX-LINKED INHERITANCE. Dr Rasime Kalkan
SEX-LINKED INHERITANCE Dr Rasime Kalkan Human Karyotype Picture of Human Chromosomes 22 Autosomes and 2 Sex Chromosomes Autosomal vs. Sex-Linked Traits can be either: Autosomal: traits (genes) are located
More informationPolyomaviridae. Spring
Polyomaviridae Spring 2002 331 Antibody Prevalence for BK & JC Viruses Spring 2002 332 Polyoma Viruses General characteristics Papovaviridae: PA - papilloma; PO - polyoma; VA - vacuolating agent a. 45nm
More informationRisk assessment and genetic counseling in families with Duchenne muscular dystrophy
Acta Myologica 2012; XXXI: p. 179-183 Risk assessment and genetic counseling in families with Duchenne muscular dystrophy Tiemo Grimm, Wolfram Kress, Gerhard Meng and Clemens R. Müller Department of Human
More informationMolecular Biology (BIOL 4320) Exam #2 May 3, 2004
Molecular Biology (BIOL 4320) Exam #2 May 3, 2004 Name SS# This exam is worth a total of 100 points. The number of points each question is worth is shown in parentheses after the question number. Good
More informationPPMD Annual Meeting, June 29 th 2018 Dr. Paolo Bettica, VP R&D
PPMD Annual Meeting, June 29 th 2018 Dr. Paolo Bettica, VP R&D Disclosure and Disclaimer Dr. Bettica is a full time employee of Italfarmaco, the manufacturer of Givinostat Givinostat (ITF2357) is currently
More informationInternational Graduate Research Programme in Cardiovascular Science
1 International Graduate Research Programme in Cardiovascular Science This work has been supported by the European Community s Sixth Framework Programme under grant agreement n LSHM-CT-2005-01883 EUGeneHeart.
More information